Targeted drug delivery strategies for precision medicines
Progress in the field of precision medicine has changed the landscape of cancer therapy.
Precision medicine is propelled by technologies that enable molecular profiling, genomic …
Precision medicine is propelled by technologies that enable molecular profiling, genomic …
Advances in immunotherapy for triple-negative breast cancer
Y Liu, Y Hu, J Xue, J Li, J Yi, J Bu, Z Zhang, P Qiu… - Molecular cancer, 2023 - Springer
Background Immunotherapy has recently emerged as a treatment strategy which stimulates
the human immune system to kill tumor cells. Tumor immunotherapy is based on immune …
the human immune system to kill tumor cells. Tumor immunotherapy is based on immune …
Epidermal growth factor receptor cell proliferation signaling pathways
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly
upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer …
upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer …
Progress and prospect of immunotherapy for triple-negative breast cancer
C Luo, P Wang, S He, J Zhu, Y Shi, J Wang - Frontiers in Oncology, 2022 - frontiersin.org
Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
LM Thorpe, H Yuzugullu, JJ Zhao - Nature Reviews Cancer, 2015 - nature.com
Abstract Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular
signalling in response to extracellular stimuli. Hyperactivation of PI3K signalling cascades is …
signalling in response to extracellular stimuli. Hyperactivation of PI3K signalling cascades is …
The PI3K/AKT pathway as a target for cancer treatment
IA Mayer, CL Arteaga - Annual review of medicine, 2016 - annualreviews.org
Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor,
which in most cases results from its dependence on an oncogene and/or loss of a tumor …
which in most cases results from its dependence on an oncogene and/or loss of a tumor …
The present and future of PI3K inhibitors for cancer therapy
Abstract Phosphoinositide 3-kinase (PI3K) signaling regulates cellular proliferation, survival
and metabolism, and its aberrant activation is one of the most frequent oncogenic events …
and metabolism, and its aberrant activation is one of the most frequent oncogenic events …
A ROR1–HER3–lncRNA signalling axis modulates the Hippo–YAP pathway to regulate bone metastasis
Bone metastases remain a serious health concern because of limited therapeutic options.
Here, we report that crosstalk between ROR1–HER3 and the Hippo–YAP pathway promotes …
Here, we report that crosstalk between ROR1–HER3 and the Hippo–YAP pathway promotes …
CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer
SF Johnson, C Cruz, AK Greifenberg, S Dust… - Cell reports, 2016 - cell.com
Although poly (ADP-ribose) polymerase (PARP) inhibitors are active in homologous
recombination (HR)-deficient cancers, their utility is limited by acquired resistance after …
recombination (HR)-deficient cancers, their utility is limited by acquired resistance after …
HER3 in cancer: from the bench to the bedside
L Gandullo-Sánchez, A Ocaña, A Pandiella - Journal of Experimental & …, 2022 - Springer
The HER3 protein, that belongs to the ErbB/HER receptor tyrosine kinase (RTK) family, is
expressed in several types of tumors. That fact, together with the role of HER3 in promoting …
expressed in several types of tumors. That fact, together with the role of HER3 in promoting …